ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Cardiotoxicity in cancer immunotherapy: a systematic review and global meta-analysis.Journal of translational medicine · 2025Pooled it
- Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors.The oncologist · 2026Trial
- Cardiac dysfunction during immune checkpoint inhibitor therapy: association with extracardiac immune-related adverse events.Cardio-oncology (London, England) · 2026Article
- T cells in acute and chronic myocarditis: from diagnosis to treatment.European heart journal · 2026Review
- Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical management algorithm.Internal medicine journal · 2026Article
- Immune checkpoint inhibitors and myocardial infarction.Journal of thrombosis and thrombolysis · 2026Review
- Advancing precision cardio-oncology: multimodal surveillance and stratified management of immunotherapy-induced cardiovascular toxicity.Frontiers in cardiovascular medicine · 2026Review
- Troponin Surveillance in Patients Receiving Immune Checkpoint Inhibitors.JACC. CardioOncology · 2025Article
- Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy.JACC. CardioOncology · 2025Article
- Immunotherapy-Associated Cardiotoxicity: Current Insights and Future Directions for Precision Cardio-Oncology.Cancers · 2025Review
- Real-Life Management of Elevated Troponin Level in Patients Treated with Immune Checkpoint Inhibitors.CJC open · 2025Article
- Risk factors of immune checkpoint inhibitor-related cardiotoxicity: a scoping review.The oncologist · 2025Article
- The predictive value of serial troponin measurements in patients treated with immune checkpoint inhibitors.The oncologist · 2025Observational
- Multimodal Imaging of Immune Checkpoint Inhibitor Myocarditis.Journal of clinical medicine · 2025Review
- Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events.Journal for immunotherapy of cancer · 2025Article
- Cancer and myocardial injury in patients with suspected acute coronary syndrome.Cardio-oncology (London, England) · 2025Article
- Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study.Frontiers in oncology · 2025Article
- Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence andJACC. CardioOncology · 2024Review
- The Good (Tumor Killing) and the Bad (Cardiovascular Complications) of Immunologic Checkpoint Inhibitors.Current cardiology reports · 2024Review
- Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors.Current oncology (Toronto, Ont.) · 2024Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 12 institutions in 6 countries.
Funding
Abstract
purposeBoth immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor (VEGFR) inhibitors are approved for advanced renal cell carcinoma treatment and can cause cardiovascular events (CVs); thus, combination therapy could lead to major adverse CV events (MACE). Cardiac serum biomarker assessment and imaging, including left ventricular ejection fraction (LVEF) monitoring, can be used to evaluate MACE.
methodsTo our knowledge, the JAVELIN Renal 101 trial, assessing avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma, is the first randomized study of ICI plus VEGFR inhibitor treatment to include prospective serial cardiac monitoring of LVEF and serum cardiac biomarkers.
resultsMACE (defined as grade ≥ 3 CV AEs) occurred in 31 patients (7.1%) in the combination arm and 17 patients (3.9%) in the sunitinib arm. Patients in the combination arm who had high baseline troponin T values were at higher risk of MACE versus patients with low values (MACE in 6/35
conclusionPatients with high baseline troponin T levels receiving ICI and VEGFR combinations may need to be monitored more closely for MACE. Routine monitoring of LVEF in asymptomatic patients is not recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.